A cyclophosphamide-induced autoimmune diabetes.
C
C
Atlan-Gepner
R
R
Bouabdallah
R
R
Valero
D
D
Coso
B
B
Vialettes
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001327:Autoimmune Diseases / Q000139:chemically induced*; D003520:Cyclophosphamide / Q000009:adverse effects*; D003922:Diabetes Mellitus, Type 1 / Q000139:chemically induced / Q000276:immunology*; D004317:Doxorubicin / Q000008:administration & dosage; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D008297:Male; D051379:Mice; D016688:Mice, Inbred NOD; D008875:Middle Aged; D011239:Prednisolone / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
D000903:Antibiotics, Antineoplastic; D018931:Antineoplastic Agents, Hormonal; D000972:Antineoplastic Agents, Phytogenic; D007166:Immunosuppressive Agents; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone